Cancer treatments that work with the immune system are making great strides, with Keytruda from Merck being perhaps the best known. Still, there is much work to be done – both in developing unprecedented new treatments, as well as treatments that might combine with our existing treatments to make them even more effective. Triumvera (try-um-VEERA) Immunologics is working on both. Dr. Paul Lammers is its CEO.
